

Syngene

Ref: Syn/CS/SE/PR/2020-21/Sep/57

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India

T +91 80 6775 8000

F +91 80 6775 8808

CIN: L85110KA1993PLC01493

www.syngeneintl.com

September 9, 2020

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Press Release

Please find enclosed the press release titled “ICMR approval for HiMedia-Syngene COVID-19 antibody test kit, ELISafe 19™”.

The press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra

Company Secretary and Compliance Officer

Press Release

ICMR approval for HiMedia-Syngene COVID-19 antibody test kit, ELISafe 19™

Mumbai, 9th September, 2020

HiMedia Laboratories, a bioscience company with expertise in media manufacturing and diagnostics, and Syngene International, an integrated research and development services company, have collaborated to manufacture ELISafe 19™, an IgG based ELISA test kit for COVID-19 now approved by the Indian Council of Medical Research (ICMR). The ELISafe 19™ antibody test kit has a sensitivity of 100% and specificity of 99%.

Commenting on the news, **Dr. Vishal G. Warke, Director R&D, Cell Culture and Immunology, HiMedia Laboratories**, said, *“We appreciate the prompt response of the ICMR in reviewing and approving the ELISafe 19™ kit. The kit is a result of a unique combination of skills: Syngene’s expertise in viral research and HiMedia’s ability to manufacture and commercialise the product. The kit is made in India for the benefit of Indian hospitals and patients and it will play a significant role in testing for SARS-CoV-2 antibodies facilitating tracking of the progression of infection and immunity to future infection.”*

Dr. Mahesh Bhalgat, Chief Operating Officer, Syngene International Ltd. added, *“Since the declaration of the COVID-19 pandemic, there has been an urgent need for simple and specific testing tools that not only detect the presence of the coronavirus but also contribute to the surveillance of the immune response to the virus. The ELISafe 19™ testing kit fills this gap. This type of serological detection of SARS-CoV-2 antibodies will generate invaluable data and provide the basis for epidemiological studies of immunity in the community: a significant advance in the management of this highly infectious disease in India.”*

The use of an IgG antibody test offers the opportunity to study and understand the percentage of population exposed to SARS-CoV-2 infection. The ELISafe19™ kit is intended for qualitative detection of IgG SARS-CoV-2 antibodies using the standard ELISA method on human serum/plasma samples. The kit will also help to identify the IgG immune status of COVID-19 recovered patients so that their plasma can be used for therapeutics.

Syngene developed the IgG based ELISA at its research facility in Bengaluru and partnered with HiMedia to manufacture and commercialise the product. HiMedia is seeking approval from the Central Drugs Standard Control Organisation (CDSCO) and will launch the kits once approval is in place.

About HiMedia

HiMedia Laboratories Pvt. Ltd. is a leading Bioscience Company of Indian origin, having expertise in innovation, and manufacturing of Microbiology, Cell Culture and Plant tissue Culture media, Molecular Biology, Diagnostics, Chemicals, Laboratory Equipment, and Hydroponics Solutions. The principal mission behind the establishment of the organization, four decades ago, was to help Indian scientific fraternity by providing world class quality products at competitive prices. With presence in over 150 countries, HiMedia ranks amongst top 3 Media Manufacturers in the world. Since Research and Development is the core foundation of HiMedia, the brand invests significant amount of its profits in R&D and is driven by a strong team of scientists and experts. Himedia's state-of-the-art manufacturing units are spread over 8 locations. Visit www.himedialabs.com for more details.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's 4200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading edge science as well as multinationals including GSK and Merck KGaA. For more details, visit www.syngeneintl.com.

Contact details

<p>HiMedia Contact</p> <p>Dr. Rahul Joshi P: +91 22- 61471919 M: 8407933119 / 8291975185 Fax: +91-22-61471920 E: rahul.joshi@himedialabs.com</p>	
<p>Syngene Contacts</p>	
<p>Investor Relations</p> <p>Krishnan G P: +9180 6891 9807 M: +91 9819992927 Fax: +91 80 2852 3423 E: Krishnan.G@syngeneintl.com</p>	<p>Media Contact</p> <p>Sandeep Nair P: +91 80 6891 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com</p>